 |
The Journal of Neuroscience, October 25, 2006, 26(43):11174-11186; doi:10.1523/JNEUROSCI.3004-06.2006
Previous Article | Next Article 
Neurobiology of Disease
Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors
Jorge M. A. Oliveira,1,2,4
Sylvia Chen,2
Sandra Almeida,4
Rebeccah Riley,2
Jorge Gonçalves,1
Catarina R. Oliveira,4
Michael R. Hayden,3
David G. Nicholls,2
Lisa M. Ellerby,2 and
A. Cristina Rego4
1Serviço de Farmacologia da Faculdade de Farmácia, Centro de Estudos de Química Orgânica, Fitoquímica e Farmacologia, Universidade do Porto, 4050-047 Porto, Portugal, 2Buck Institute for Age Research, Novato, California 94945, 3Department of Medical Genetics, Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4H4, and 4Center for Neuroscience and Cell Biology and Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
Correspondence should be addressed to Prof. A. Cristina Rego Institute of Biochemistry, Faculty of Medicine, Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal. Email: acrego{at}cnc.cj.uc.pt
Evidence suggests that neuronal dysfunction in Huntington's disease (HD) striatum involves deficits in mitochondrial function and in Ca2+ handling. However, the relationship between mitochondria and Ca2+ handling has been incompletely studied in intact HD striatal cells. Treatment with histone deacetylase (HDAC) inhibitors reduces cell death in HD models, but the effects of this promising therapy on cellular function are mostly unknown. Here, we use real-time functional imaging of intracellular Ca2+ and mitochondrial membrane potential to explore the role of in situ HD mitochondria in Ca2+ handling. Immortalized striatal (STHdh) cells and striatal neurons from transgenic mice, expressing full-length mutant huntingtin (Htt), were used to model HD. We show that (1) active glycolysis in STHdh cells occludes the mitochondrial role in Ca2+ handling as well as the effects of mitochondrial inhibitors, (2) STHdh cells and striatal neurons in the absence of glycolysis are critically dependent on oxidative phosphorylation for energy-dependent Ca2+ handling, (3) expression of full-length mutant Htt is associated with deficits in mitochondrial-dependent Ca2+ handling that can be ameliorated by treatment with HDAC inhibitors (treatment with trichostatin A or sodium butyrate decreases the proportion of STHdh cells losing Ca2+ homeostasis after Ca2+-ionophore challenging, and accelerates the restoration of intracellular Ca2+ in striatal neurons challenged with NMDA), and (4) neurons with different response patterns to NMDA receptor activation exhibit different average somatic areas and are differentially affected by treatment with HDAC inhibitors, suggesting subpopulation or functional state specificity. These findings indicate that neuroprotection induced by HDAC inhibitors involves more efficient Ca2+ handling, thus improving the neuronal ability to cope with excitotoxic stimuli.
Key words: Huntington's disease; striatal neurons; excitotoxicity; mitochondria; calcium; HDAC inhibitors
Received Aug. 12, 2005;
accepted Aug. 29, 2006.
Correspondence should be addressed to Prof. A. Cristina Rego Institute of Biochemistry, Faculty of Medicine, Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal. Email: acrego{at}cnc.cj.uc.pt
This article has been cited by other articles:

|
 |

|
 |
 
J. M. A. Oliveira and J. Goncalves
In Situ Mitochondrial Ca2+ Buffering Differences of Intact Neurons and Astrocytes from Cortex and Striatum
J. Biol. Chem.,
February 20, 2009;
284(8):
5010 - 5020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Seo, W. Kim, and O. Isacson
Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients
Hum. Mol. Genet.,
October 15, 2008;
17(20):
3144 - 3153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Quintanilla, Y. N. Jin, K. Fuenzalida, M. Bronfman, and G. V. W. Johnson
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells: POSSIBLE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} (PPAR{gamma}) IN THE PATHOGENESIS OF HUNTINGTON DISEASE
J. Biol. Chem.,
September 12, 2008;
283(37):
25628 - 25637.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Orr, S. Li, C.-E. Wang, H. Li, J. Wang, J. Rong, X. Xu, P. G. Mastroberardino, J. T. Greenamyre, and X.-J. Li
N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking
J. Neurosci.,
March 12, 2008;
28(11):
2783 - 2792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. B. Fernandes, K. G. Baimbridge, J. Church, M. R. Hayden, and L. A. Raymond
Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease
J. Neurosci.,
December 12, 2007;
27(50):
13614 - 13623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson
The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis
Hum. Mol. Genet.,
January 1, 2007;
16(1):
61 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|